Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer

V Michalaki¹, K Syrigos², P Charles³ and J Waxman*,¹

¹Department of Cancer Medicine, Faculty of Medicine, Imperial College of Science, Technology & Medicine, Hammersmith Campus Du Cane Road, London W12 ONN, UK; ²Third Department of Medicine, University of Athens, 40 Kifissias and Arkadias, 115 25 Athens, Greece; ³Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College of Science, Technology & Medicine, London, UK

Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) are important multifunctional cytokines involved in tumour growth and metastasis. In this study, we have measured serial levels of serum IL-6 and TNF-α in prostate cancer patients. A total of 80 patients with carcinoma of the prostate and 38 controls were studied. Three patient groups, with small bulk localised, large volume localised and metastatic prostate cancer, were assessed. Serum IL-6 and TNF-α levels were measured and correlated with clinicopathological variables and patient survival. Serial changes in these cytokines were also assessed and related to disease progression in 40 patients with recurrent prostate cancer.

Serum IL-6 levels in patients with metastatic disease (9.3 ± 7.8 pg ml⁻¹) were higher than those in patients with localised disease (1.3 ± 0.8 pg ml⁻¹, P < 0.001). Significantly elevated levels of TNF-α were found in metastatic disease (6.3 ± 3.6 pg ml⁻¹) compared with localised disease (1.1 ± 0.5 pg ml⁻¹, P < 0.001). The levels of both cytokines were directly correlated with the extent of the disease. Serial analysis in 40 patients with recurrent tumours showed that both cytokines became elevated at the point of prostate-specific antigen progression. In conclusion, these results suggest that IL-6 and TNF-α correlate with the extent of disease in patients with prostate cancer and may be monitored in conjunction with other disease markers.

Prostate cancer is the most common cancer in men in the Western world and the second most common cause of male cancer deaths. The progression of prostate cancer to a metastatic state and to hormone independence is thought of as a multi-step process involving growth factors, hormones and cytokines (Bok and Small, 2002; Huss et al, 2001).

Although there are clear descriptions of the relationship of cytokines to the development and progression of many cancers, there are few published observations relevant to prostate cancer. Surprisingly perhaps for a tumour where there is such clear evidence of a primary hormonal basis to its development, there is emerging evidence of cytokine involvement. IL-6 and TNF-α, two cytokines with multiple and overlapping biological properties, are involved in prostate cancer development (Shariat et al, 2001; Smith et al, 2001).

This involvement of IL-6 at a cellular level with the processes of cancer control is reflected by the results of serum studies of cancer patients, where IL-6 may reflect prognosis and tumour load. Elevated IL-6 levels have been associated with advanced stage and metastasis-related morbidity (Adler et al, 1999; Nakashima et al, 2000; Wise et al, 2000). Thus, it has been recently reported that patients with metastatic ovarian cancer and patients with metastatic renal cell carcinoma have higher serum IL-6 levels than those without disseminated disease (Blay et al, 1992; Scambia et al, 1995). It has also been demonstrated that elevated IL-6 levels are associated with a poor prognosis in tumours such as non-small-cell lung cancer. The ontological role of IL-6 in this process is not known (De Vita et al, 1998).

Studies of IL-6 in prostate carcinoma provide support for the hypothesis that direct local production of IL-6 by malignant cells significantly contributes to elevated serum levels (Deeble et al, 2001).

IL-6 and TNF-α are considered the major mediators of a network of interactive signals. TNF-α is a pleiotropic cytokine, which like IL-6 has been shown to be associated with cancer progression. It is of interest that many androgen-insensitive prostate cancer cells are TNF-α insensitive. This may be because of the upregulation of a series of antiapoptotic genes involved in a network of paracrine and autocrine loops that modulate prostate carcinoma cell activity, and these include the nuclear factor-kappaB (NF-κB) family of transcription factors (Muenchen et al, 2000).

In a series of 122 patients with renal cell carcinoma, Yoshida et al (2002) demonstrated that serum levels of TNF-α directly correlated with advanced stage grouping as compared with controls, and suggested that TNF-α could be useful in the early diagnosis of the disease. There has been a single study by Nakashima et al (1998), where TNF-α has been shown to be associated with prostate cancer progression. Serum TNF-α activity was positive in 76% of the patients with relapsed disease who had a significantly higher mortality rate than those with undetectable serum TNF-α levels.

In this study, we measured the serum levels of IL-6 and TNF-α in prostate cancer patients, using a highly sensitive ELISA kit, in an attempt to define their association with clinicopathological features and clinical outcome.
Materials and Methods

Patients

A total of 80 men with prostate cancer (mean age 74.5 ± 7.5 years) were included in this prospective study and compared with two normal control groups, consisting of 12 men presenting for prostate cancer screening who had no prior history of cancer or chronic disease, a normal digital rectal examination and a prostate-specific antigen (PSA) of less than 2.0 ng ml⁻¹, which is in the PSA range with an estimated prostate cancer detection probability of less than 1% in the first 4 years after screening (Smith et al, 1996), and 26 patients with biopsy-proven benign prostatic hyperplasia (1).

The mean control age was 67.5 ± 6.8 years. All patients had histological confirmation of the diagnosis of prostate cancer by needle biopsy or by transurethral resection of the prostate. Each patient was staged by clinical examination, bone scanning and computed tomography of the abdomen and pelvis. For the histologic grade the Gleason scoring was used. No patients had evidence of active infection or inflammatory disease.

To further evaluate the association between IL-6 and TNF-α and the progression of the disease, we assessed the serial changes of both cytokines in patients with recurrent disease. Therefore, at the time of the study, three samples from each patient with locally advanced or metastatic cancer were collected. The samples were chosen to represent the time points of presentation prior to treatment, the first evidence of PSA increase beyond the normal range and disease progression.

Out of 26 patients with localised disease, 12 were initially treated with radiation therapy or surgery, whereas all patients with locally advanced or metastatic disease were treated with endocrine therapy using a luteinising hormone-releasing analogue and flutamide. Neither patients with metastatic disease nor patients with localised disease were treated before serum collection.

Sample collection and cytokine measurements

Blood samples were prospectively collected with the appropriate Ethical Committee permissions, from patients attending Oncology Outpatients Clinics at the Hammersmith Hospital. Each sample had been collected in a Vacutainer, (Becton Dickinson, Plymouth, UK) and serum was separated within 1 h of blood collection after spinning for 15 min at 1500 g. The serum was stored without preservative at −70°C and then thawed just prior to testing (2).

Serum IL-6 and TNF-α concentrations were determined using the commercially available enzyme-linked immuno-sorbent assay (ELISA), US (Ultra sensitive), kit supplied by Biosource International (CA, USA). The assays employ the quantitative sandwich enzyme immunoassay technique using recombinant human IL-6 and TNF-α, with antibodies raised against the recombinant proteins, respectively. The IL-6 ELISA assay has a performance sensitivity of less than 0.16 pg ml⁻¹ with the minimum detectable level at 104 fg ml⁻¹. The TNF-α assay has a performance sensitivity of less than 0.5 pg ml⁻¹ and the minimum detectable level was 0.09 pg ml⁻¹. Optical density was read with a microtiter plate reader by dual wavelength at 450 nm. All samples were assayed in duplicate.

Elevated serum levels of the studied cytokines were defined as being greater than the 95th percentile values in the healthy control group. This resulted in a cutoff value of 2.1 and 1.9 pg ml⁻¹ for IL-6 and TNF-α, respectively.

Follow-up

Follow-up data were obtained for all patients. Details of clinical progress and survival were obtained from Hospital and General Practice records and traced to Death Certificates where appro-
bone metastases had similar IL-6 and TNF-α levels (P = 0.31 and P = 0.28), which were higher than those in the group with localised disease (P < 0.001).

Serum IL-6 and TNF-α levels were significantly elevated in patients with Gleason score > 6 (mean 7.8 ± 5.3 pg ml⁻¹, median 4.0 pg ml⁻¹, P = 0.001 with respect to IL-6; mean 5.2 ± 3.7 pg ml⁻¹, median 5.1 pg ml⁻¹, P = 0.009 with respect to TNF-α).

Univariate analysis showed a positive correlation between disease stage and IL-6 and TNF-α levels (IL-6: correlation coefficient, 0.32; P < 0.001; TNF-α: correlation coefficient 0.29; P = 0.008). TNF-α levels were also correlated with PSA (correlation coefficient, 0.41; P < 0.001).

To identify the variables of prognostic significance in all of the patients with prostate cancer, univariate analysis of each variable was performed in relation to the survival time. On univariate Cox proportional hazards regression analysis (Table 3), serum IL-6 (above the cutoff level of 2.1 pg ml⁻¹) and serum TNF-α (above the cutoff level of 1.9 pg ml⁻¹) were significant prognostic factors for survival, along with Gleason sum and serum PSA (categorised as above or below the cutoff level of 1.9 pg ml⁻¹; Figure 1).

By the log-rank test, we found that patients with localised disease and serum IL-6 levels above the cutoff level (2.1 pg ml⁻¹) had an increased probability of poor overall survival. Similarly, the same group of patients with serum TNF-α levels above the cutoff level (1.9 pg ml⁻¹) had the worst outcome (P = 0.04; Figure 2).

However, the multivariate regression analysis failed to confirm these cytokines as significant independent prognostic variables for cancer-specific survival.

Serial changes in levels of cytokines at presentation, PSA progression and symptom progression

To further evaluate the association between IL-6 and TNF-α and the progression of the disease, we additionally assessed the serial changes of these cytokines in 40 patients with bulky locally advanced or metastatic cancer, at the time points of presentation prior to treatment, at the first time point when PSA started to rise and the point at which there was progression to symptomatic recurrent disease with bone pain or increased obstructive urinary symptoms (Figure 3).

Analysis of the serial measurements revealed significant differences in both cytokines during the evolution of the disease. The levels of each cytokine were significantly higher at the time of biochemical relapse (mean 3.1 ± 1.47, P < 0.001 and 4.5 ± 3.4, P < 0.01 for IL-6 and TNF-α, respectively), or than at the point of biochemical relapse (mean 3.1 ± 1.47, P < 0.001 and 4.5 ± 3.4, P < 0.01 for IL-6 and TNF-α, respectively).

Table 1 Patients’ characteristics

| Patients | No | % |
|----------|----|---|
| Clinical stage | | |
| T1a | 4 | 5 |
| T1b+c | 7 | 8.8 |
| T2a | 8 | 10 |
| T2b | 4 | 5 |
| T2c | 3 | 3.8 |
| T3 | 9 | 11.2 |
| T4 | 5 | 6.2 |
| M1 | 40 | 50 |
| Gleason score | | |
| 2–4 | 12 | 14 |
| 5–6 | 50 | 63 |
| 7–10 | 18 | 23 |

Table 2 Serum levels of IL-6 and TNF-α in all prostate cancer patients and controls according to stage

| IL-6 (pg ml⁻¹) | n | P-value* | Mean ± s.d. | 95% confidence intervals |
|----------------|---|----------|-------------|--------------------------|
| P. cancer (all) | 80 | 0.031 (vs controls) | 5.65 ± 6.74 | 4.15 to 7.15 |
| Localised | 26 | <0.001 (vs metastatic) | 1.27 ± 0.81 | 0.93 to 1.59 |
| Locally adv. | 14 | 0.001 (vs metastatic) | 3.50 ± 2.88 | 1.82 to 5.16 |
| Metastatic | 40 | <0.001 (vs controls) | 9.26 ± 7.81 | 6.76 to 11.7 |
| Controls | 12 | 1.13 ± 0.63 | 0.73 to 1.53 |
| BPH | 26 | 1.20 ± 0.49 | 1.00 to 1.40 |

| TNF-α (pg ml⁻¹) | n | P-value* | Mean ± s.d. | Lower bound | Upper bound |
|-----------------|---|----------|-------------|-------------|------------|
| P. cancer (all) | 80 | 0.003 (vs controls) | 4.30 ± 3.69 | 3.47 to 5.12 |
| Localised | 26 | 0.03 (vs metastatic) | 1.38 ± 0.69 | 1.10 to 1.66 |
| Locally adv. | 14 | 0.02 (vs metastatic) | 3.90 ± 3.43 | 1.90 to 5.87 |
| Metastatic | 40 | <0.001 (vs controls) | 6.34 ± 3.66 | 5.16 to 7.51 |
| Controls | 12 | 1.08 ± 0.55 | 0.73 to 1.43 |
| BPH | 26 | 1.21 ± 0.65 | 0.94 to 1.47 |

*Mann–Whitney U test.
The univariate logistic regression analysis revealed that both cytokines were significant predictors for the evolution of the disease. Thus, considering the baseline IL-6 levels, the relative risk for development of biochemical progression was 1.9 (95% CI, 1.088 – 3.281; \( P = 0.024 \)). Similarly, for TNF-\( \alpha \) the relative risk was slightly higher at 2.1 (95% CI, 1.144 – 4.12; \( P = 0.018 \)).

**DISCUSSION**

Elevated serum levels of specific cytokines have been previously described in prostate cancer benign prostate hyperplasia and in prostate cancer cell lines (Chen et al, 2000; Mizokami et al, 2000).

Twilley et al (1995) showed elevated serum IL-6 levels in 47% of 73 patients with advanced hormone refractory prostate cancer and suggested that this cytokine mediated morbidity in patients with metastatic disease. Likewise, Drachenberg et al (1999) reported high concentrations of IL-6 in men with hormone refractory prostate cancer compared to normal controls, benign prostatic hyperplasia, prostatitis and localised or recurrent disease.

We report elevated serum levels of the cytokines IL-6 and TNF-\( \alpha \) in patients with prostate cancer as compared with controls. There was a strong association between the serum levels of the cytokines, disease stage and the presence of metastatic disease. TNF-\( \alpha \) was significantly elevated in patients with metastatic cancer compared with the two groups of patients with localised disease and controls, and was correlated with increasing PSA. In contrast, IL-6 was correlated with tumour burden independently of PSA.

In patients with progressive disease, both IL-6 and TNF-\( \alpha \) were elevated at the point of biochemical progression and further raised at symptomatic progression. These cytokines may therefore provide additional markers to PSA that reflect the activity of prostate cancer.

Our results confirm the findings of previous studies and add to the literature by documenting the significance of IL-6 and TNF-\( \alpha \) as predictors of progressive disease.

We postulate that serum IL-6 and TNF-\( \alpha \) levels might be useful prognostic markers with regard to progression to biochemical or symptomatic relapse based on the results of serial measurements. To our knowledge, this is the first time in the reported literature that monitoring of serial serum concentrations of these cytokines has been suggested as possible indicators of disease progression. However, the multivariate regression analysis failed to confirm these cytokines as significant independent prognostic variables for patient survival.

IL-6 is known to promote the proliferation and metastatic potential of cancer cells.

This cytokine has been characterised as a prostate exocrine gene product that interacts with its receptor in prostate cells, regulating proliferation and differentiation, and in prostate cancer cell lines activates androgen receptor (AR).

IL-6 signalling is mediated through the Janus kinase (JAK), signal transducer, activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK), which induces AR-mediated gene activation in prostate cancer (Hobisch et al, 1998; Lou et al, 2000; Spiotto and Chung, 2000). Several in vitro studies on prostate cancer cell lines suggest that prostate cancer cells
themselves are secreting a major portion of IL-6, although other sources cannot be excluded. As prostate cancer cells also express high levels of IL-6 receptor, IL-6 may elicit both paracrine and autocrine responses. Thus, during the progression of prostate cancer to the hormone refractory phenotype, IL-6 undergoes a functional transition from paracrine growth inhibitor to autocrine growth stimulator (Hobisch et al., 1998; Deeble et al., 2001). These androgen-insensitive cells are also TNF-α insensitive. This is attributed to the constitutive activation of antiapoptotic genes, since TNF-α activates cell survival and cell death mechanisms simultaneously and can influence cell growth by apoptotic and nonapoptotic mechanisms (Muench et al., 2000).

However, many signalling pathways through which IL-6 and TNF-α mediate their effects have not been defined yet. A better understanding of how these cytokines contribute to the pathophysiology of prostate cancer would provide new targets for therapeutic intervention.

In conclusion, viewed in the context of similar observations made for other cancers, these data further support a relationship between elevated IL-6 and TNF-α levels and metastatic prostate cancer. Both cytokines correlate with the extent of disease and should be monitored in conjunction with other disease indicators. Although it is possible that these cytokines have a casual role in cancer progression, it is also of course clear that they may have a bystander role in malignancy.

REFERENCES

Adler HL, Mccurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta in patients with metastatic prostatic carcinoma. J Urol 161: 182–187

Blay JY, Negrier S, Combarot V, Attali S, Gofflot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317–3322

Bok RA, Small EJ (2002) Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2: 918–926

Chen T, Wang LH, Farrar WL (2000) Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132–2135

De Vita F, Orditura M, Auriemma A, Infusino S, Roccigano A, Catalano G (1998) Serum levels of interleukin 6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5: 649–652

Deeble PD, Murphy DJ, Parsons SJ, Cox ME (2001) Interleukin-6 and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 8471–8482

Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127–133

Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640–4645

Huss WJ, Barrios RJ, Foster BA, Greenberg NM (2003) Differential expression of specific FGFr ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 54: 8–16

Lou W, Ni Z, Dyer K, Tweeky DJ, Gao AC (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42: 239–242

Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T (2000) Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 164: 800–805

Muenchung HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ (2000) Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha 'super-repressor'. Clin Cancer Res 6: 1969–1977

Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702–2706

Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4: 1743–1748

Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle G, Mancuso S (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71: 354–356

Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008–1015

Smith DS, Catalona WJ, Herschman JD (1996) Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276: 1309–1315

Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET (2001) Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33–40

Spiliotto MT, Chung TD (2000) STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42: 88–98

Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542–549

Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164: 722–725

Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T (2002) Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 6: 1396–1400